Skip to main content
. 2020 Dec 31;42(4):517–527. doi: 10.1093/carcin/bgaa144

Figure 5.

Figure 5.

PTP1B∆2–4 has protective effects against cytotoxic agents in the cHL cell line L-428. (A–C) Altered proliferation of the L-428 cells stably transfected with pcDNA3.1 (EV), or with HA-PTP1BWT, HA-PTP1B∆6 or HA-PTP1B∆2–4 after treatment with the indicated amount of etoposide (A), gemcitabine (B) and doxorubicin (C) measured by MTS proliferation assay. The untreated cells served as control. Mean of three independent MTS assay measurements is depicted. (D) Proliferation of L-428 cells stably transfected with pcDNA3.1 (EV), or with HA-PTP1BWT, HA-PTP1B∆6 or HA-PTP1B∆2–4 either stimulated with 20 ng/ml IL-4 for 48 h, laced with 1 ng/ml gemcitabine or laced with 1 ng/ml gemcitabine in combination with IL-4 stimulation (20 ng/ml, 48 h) measured by MTS proliferation assay. The untreated cells served as control. Mean of four independent MTS assay measurements is depicted. (A–D) Mean values and standard error of mean (SEM) are depicted. Comparisons were performed between untreated control and individual treatment for each stable cell line. Significances are calculated using Student’s t-test (P < 0.05 was regarded as significant).